Compare
Context Therapeutics Inc. vs Werewolf Therapeutics, Inc. vs Corvus Pharmaceuticals, Inc. vs Inovio Pharmaceuticals, Inc.
| Latest fiscal year | Context Therapeutics Inc. CNTX | Werewolf Therapeutics, Inc. HOWL | Corvus Pharmaceuticals, Inc. CRVS | Inovio Pharmaceuticals, Inc. INO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $65.3K |
| Revenue growth (YoY) | n/a | n/a | n/a | -70.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$36.12M | -$60.82M | -$15.28M | -$84.95M |
| EPS (Diluted) | -$0.38 | -$1.33 | -$0.53 | -$1.81 |
| Operating cash flow | -$26.39M | -$60.29M | -$32.80M | -$88.63M |
| Free cash flow | -$26.42M | -$60.29M | -$32.97M | -$88.92M |
| Cash & equivalents | $66.00M | $57.05M | $4.58M | $44.27M |
| Total assets | $68.49M | $69.40M | $71.12M | $74.31M |
| Total liabilities | $8.02M | $44.59M | $9.91M | $50.21M |
| Shareholders' equity | $60.47M | $24.80M | $61.20M | $24.10M |
| Return on year-end equity | -59.7% | -245.2% | -25.0% | -352.5% |
| Shares outstanding | 91.88M | 48.60M | 74.70M | 69.00M |
Revenue, most recent five fiscal years
| Fiscal year | Context Therapeutics Inc. | Werewolf Therapeutics, Inc. | Corvus Pharmaceuticals, Inc. | Inovio Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $65.3K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $217.8K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $832.0K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $10.26M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $1.77M Ended 2021-12-31 |